Neoplasm Antigens (Tumor Antigens)

Subscribe to Selected New Research on Neoplasm Antigens

1577 relevant articles (44 outcomes, 152 trials/studies) found for this Bio-Agent

Description: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.

Also Known As:

Tumor Antigens; Antigens, Neoplasm; Antigens, Tumor

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 931

Antigens: 95584

Neoplasm Antigens: 1577

Prostate-Specific Antigen: 7163

Carcinoembryonic Antigen: 5605

Tumor Viral Antigens: 2017

Neprilysin: 651

squamous cell carcinoma-related antigen: 515

Tissue Polypeptide Antigen: 472

antigen CYFRA21.1: 315

tumor-associated antigen 72: 252

Carbohydrate Tumor-Associated Antigens: 238

DNA topoisomerase II alpha: 207

CD147 Antigens: 198

CD30 Antigens: 185

tumor-associated antigen GA733: 181

tumor-associated transplantation antigen: 164

oncofetal antigens: 130

HMW-MAA: 117

blocking factor: 96

melanoma-specific antigens: 91

pancreatitis-associated protein: 88

integrin alphavbeta6: 39

carcinoma-associated antigen 17-1A: 25

colon-specific antigen: 24

bladder tumor-associated antigen: 13

gastro-intestinal mucus-associated antigens: 13

MART1 antigen: 13

antigen G250: 11

SPan-1 pancreatic associated antigen: 11

B5 antigen: 9

gp43 tumor-associated antigen: 8

ovarian tumor associated antigen: 8

sarcoma glycoprotein gp96 rejection antigens: 8

organ-specific neoantigen: 7

P.polypeptide: 5

pancreas-specific antigen: 5

TA90 immune complex: 5

UBC antigen: 5

22-1-1 antigen: 4

gamma-fetal antigen: 4

human MAGEA1 protein: 4

human MGr1-antigen: 4

mouse Q5 antigen: 4

osteosarcoma-associated antigen: 4

A6H antigen: 3

mouse pRL1a protein: 3

beta1-meconial antigen: 2

human malignancy-associated nucleolar antigen: 2

Ma2 antigen: 2

NB-p260 antigen: 2

Nova antigen: 2

4-O-acetyl-N-glycolylneuraminyl lactosylceramide: 1

4B5 antigen: 1

antigen p102: 1

brain-associated small-cell lung cancer antigen: 1

Cora antigen: 1

EGP314 antigen: 1

formalinized extracellular antigen: 1

HBA-71 tumor antigen: 1

human CTAGE1 protein: 1

interspecific embryonic antigen-1: 1

leukemoembryonic antigens: 1

mammary carcinoma antigen: 1

adenocarcinoma antigen recognized by T cells-1

AK-5 antigen

antigen p200

avian Marek's disease tumor-associated surface antigen

DF3 breast-carcinoma-associated antigen

glycoprotein GP37

human 55-kDa melanoma-associated cell surface protein

human AD034 antigen

human adenoma-associated antigen glycoprotein 87

human BJ-HCC-2 protein

human breast cancer antigen NY-BR-1

human breast cancer-associated antigen 200

human CA9 protein

human CAGE1 protein

human cancerocerebral antigen

human CCDC110 protein

human clusterin-associated protein 1

human colon cancer-specific antigen 2

human colon-ovarian tumor antigen

human colorectal carcinoma-associated antigen

human colorectal tumor-associated antigen

Experts

1.	Yang, Xiao-Feng: 3 articles (03/2007 - 10/2005)
2.	Finn, Olivera J: 3 articles (01/2006 - 01/2004)
3.	Disis, Mary L: 2 articles (08/2007 - 10/2006)
4.	Yang, Fan: 2 articles (03/2007 - 10/2005)
5.	Liu, Bin: 2 articles (12/2006 - 07/2005)
6.	Oosterwijk, Egbert: 2 articles (08/2003 - 11/2002)
7.	Bleumer, Ivar: 2 articles (08/2003 - 11/2002)
8.	Jäger, D: 2 articles (01/2001 - 04/2000)
9.	Chen, Y T: 2 articles (05/2000 - 04/2000)
10.	Tüting, Thomas: 1 article (10/2008)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2007 - "This is the first report to show that most established tumors were successfully eradicated by collaboration of potent antitumor immunity and anti-angiogenic effects by vaccination with tumor antigens and helper-activating analogs. " 06/28/2002 - "A paradox may emerge when vaccination is attempted in these two groups of subjects, with the second group being more prone to develop an effective immune response if the vaccine is potent enough to activate naive T cells, while the first has probably already eliminated most of the tumor antigens potentially recognizable by the host T cells owing to the previous selection made by the immune response developed early during tumor growth. " 01/01/2006 - "The work of my laboratory aims to provide evidence in animal models as well as in cancer patients that immune system can control cancer growth and that this important function can be improved through vaccination with well-defined tumor antigens." 01/01/1982 - "In contrast, when a sufficient amount of tumor antigens (higher dose of tumor cells injected and CY injection delayed) elicited an anti-YAS immune response that was not suppressed by early injection of CY (CY administered 5 days after the tumor) effective eradication of tumor cells and anti-YAS resistance in cured animals were observed." 10/01/2002 - "However, recent studies suggest that therapeutic strategies that have mainly focused on the use of CD8+ T cells (and MHC class I-restricted tumor antigens) may not be effective in eliminating cancer cells in patients. " Order ALL the reference details at left...
2.	Melanoma (Melanoma, Malignant) 09/01/1998 - "CONCLUSION: PMCV induces both humoral and cell-mediated immune responses to melanoma-associated tumor antigens, the type and strength of which appear to be directly related to its therapeutic efficacy." 01/01/2004 - "BACKGROUND: Early clinical trials, mostly in the setting of melanoma, have shown that dendritic cells (DCs) expressing tumor antigens induce some immune responses and some clinical responses. " 12/01/1996 - "A large majority of these studies focused on melanoma-associated tumor antigens because of the collective evidence that the immune system can influence the pathogenesis of melanoma, and because of the well-documented, although limited, success of immunotherapeutic modalities in melanoma patients. " 05/15/1990 - "This study attempts to characterize human melanoma-associated tumor antigens that are recognized by autologous T-lymphocyte clones. " 04/01/1988 - "Immunologic studies of melanoma tumor antigens have shown a similar variability. " Order ALL the reference details at left...
3.	Glioma (Gliomas) 02/01/2005 - "Over the past three years, studies in glioma patients have characterized tumor antigens on human gliomas, identified some of the immune cells involved in beneficial anti-glioma immunity and examined how gliomas may be altered by sub-lethal immune influences, providing a glimpse of the strength with which immunity influences glioma clinical outcome. " 01/01/2005 - "Recent studies in glioma patients have characterized tumor antigens on human gliomas, identified some of the immune cells involved in beneficial anti-glioma immunity, and examined how gliomas may be altered by sub-lethal immune influences. " 03/25/2008 - "Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat." 02/01/2006 - "OBJECT: It remains unclear whether malignant glioma cells can deliver tumor antigens efficiently to major histocompatibility complex (MHC) Class I molecules. " 06/01/1999 - "These dendritic cells were then pulsed (cocultured) ex vivo with acid-eluted tumor antigens from 9L glioma cells. " Order ALL the reference details at left...
4.	Pancreatic Neoplasms (Pancreatic Cancer) 06/01/2009 - "Protein microarrays have been used to explore whether a humoral response to pancreatic cancer-specific tumor antigens has utility as a biomarker of pancreatic cancer. " 11/23/1997 - "[Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases]" 01/01/1980 - "Tumor antigens as related to pancreatic cancer." 04/01/2004 - ": Human tumor antigens recognized by T cells have been recently identified in various cancers, including pancreatic cancer. " 10/10/2005 - "To identify tumor antigens useful for diagnosis and immunotherapy of patients with pancreatic ductal adenocarcinoma, we applied a SEREX approach with a cDNA library made from 5 pancreatic cancer cell lines and sera obtained from 8 patients with pancreatic cancer, and isolated total 32 genes, including 14 previously characterized genes and 18 genes with unknown functions. " Order ALL the reference details at left...
5.	Neoplasm Metastasis (Metastasis) 08/01/2008 - "RESULTS: TIL in colorectal liver metastases responding against tumor antigens were present in most patients. " 01/19/2007 - "Metastasis tumor antigens, an emerging family of multifaceted master coregulators." 05/25/1997 - "We have demonstrated that T cells that are sensitized to tumor antigens and then ex vivo cultured are capable of eradicating pulmonary metastases. " 01/01/1972 - "[Detection of neoplasm antigens in regional lymph node metastases]" 03/01/2001 - "This patient, with evidence of tumor-reactive CTLs targeted to several tumor antigens in a tumor-involved lymph node and with evidence of a circulating memory T-cell response, has remained disease-free for 6 years, despite prior bulky nodal metastasis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antigens
2.	Monoclonal Antibodies
3.	Peptides
4.	Antibodies
5.	Vaccines
6.	Cancer Vaccines
7.	RNA (Ribonucleic Acid)
8.	Cytokines
9.	DNA (Deoxyribonucleic Acid)
10.	Complement System Proteins (Complement)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Radioimmunotherapy
4.	Homologous Transplantation (Allograft)
5.	Transplants (Transplant)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>